Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia

AIDS

Volumn 25, Issue 5, 2011, Pages 665-669

  Gallien, Sébastien ^a   Delaugerre, Constance ^b   Charreau, Isabelle ^c   Braun, Joséphine ^c   Boulet, Thomas ^c   Barrail Tran, Aurélie ^d   De Castro, Nathalie ^b   Molina, Jean Michel ^b   Kuritzkes, Daniel R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c INSERM   (France)

^d BICÊTRE HOSPITAL   (France)

Author keywords

HIV 1; integrase inhibitor; low level viremia; raltegravir; resistance mutation; treatment experienced

Indexed keywords

ENFUVIRTIDE; INTEGRASE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROVIRUS; RANDOMIZED CONTROLLED TRIAL; VIREMIA; VIRUS GENE; VIRUS LOAD; VIRUS MUTATION;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MALE; MUTATION; PYRROLIDINONES; VIREMIA;

EID: 79952443361     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283445834     Document Type: Article

References (16)

1. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatmentnaive patients with HIV-1 infection: a multicentre, doubleblind randomised controlled trial. Lancet 2009; 374:796-806.
2. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
3. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365.
4. Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396-407.
5. De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, et al. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis 2009; 49:1259-1267.
6. De Castro N, Braun J, Charreau I, De Truchis P, Jeanblanc F, Verdon R, et al. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1 infected patients: final results of the randomized ANRS 138 Trial (EASIER). In 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa; 2009.
7. Goldwirt L, Barrail-Tran A, Da Cruz M, Taburet AM, Furlan V. Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:456-460.
8. Le Moing V, Chene G, Carrieri MP, Alioum A, Brun-Vezinet F, Piroth L, et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16:21-29. (Pubitemid 34062178)
9. Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009; 83:11440-11446.
10. Hu Z, Kuritzkes DR. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr 2010; 55:148-155.
11. Garvey EP, Johns BA, Gartland MJ, Foster SA, Miller WH, Ferris RG, et al. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother 2008; 52:901-908. (Pubitemid 351358368)
12. Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, et al. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res 2008; 80:213-222.
13. Caby F, Valin N, Marcelin AG, Schneider L, Andrade R, Guiguet M, et al. Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatmentexperienced HIV-infected patients. Scand J Infect Dis 2010; 42:527-532.
14. Charpentier C, Roquebert B, Colin C, Taburet AM, Fagard C, Katlama C, et al. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen. AIDS 2010; 24:2651-2656.
15. Garcia-Gasco P, Maida I, Blanco F, Barreiro P, Martin-Carbonero L, Vispo E, et al. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother 2008; 61: 699-704. (Pubitemid 351324637)
16. Sungkanuparph S, Groger RK, Overton ET, Fraser VJ, Powderly WG. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med 2006; 7:437-441. (Pubitemid 44269810)